{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:51Z","timestamp":1790717211481,"version":"4.1.0"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0235445","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T19:28:58Z","timestamp":1593545338000},"page":"e0235445","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3452-350X","authenticated-orcid":true,"given":"Michael W.","family":"Traeger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa E.","family":"Pedrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela K.","family":"van Santen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"El-Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Asselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Polkinghorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Membrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Bramwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Stoov\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"pone.0235445.ref001","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021","year":"2016"},{"issue":"12","key":"pone.0235445.ref002","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/jvh.12975","article-title":"Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings","volume":"25","author":"N Scott","year":"2018","journal-title":"J Viral Hepat"},{"issue":"8","key":"pone.0235445.ref003","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1136\/gutjnl-2016-311504","article-title":"Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model","volume":"66","author":"N Scott","year":"2017","journal-title":"Gut"},{"key":"pone.0235445.ref004","unstructured":"National Hepatitis C Strategy 1999\u20132000 to 2003\u20132004. Canberra, Australia: Commonwealth Department of Health and Aged Care;2000."},{"key":"pone.0235445.ref005","unstructured":"November 2015 positive recommendations. Canberra, Australia: Pharmaceutical Benefits Advisory Committee (PBAC) 2015."},{"key":"pone.0235445.ref006","unstructured":"Schedule of pharmaceutical benefits. Canberra, Australia: Commonwealth of Australia Department of Health 2015."},{"issue":"1","key":"pone.0235445.ref007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13186","article-title":"The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment","volume":"37","author":"A Kandeel","year":"2017","journal-title":"Liver Int"},{"key":"pone.0235445.ref008","unstructured":"Monitoring hepatitis C treatment uptake in Australia (Issue 10). The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia;2019."},{"issue":"9","key":"pone.0235445.ref009","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/apt.15210","article-title":"Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia","volume":"49","author":"JS Doyle","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0235445.ref010","doi-asserted-by":"crossref","unstructured":"Razavia H, Gonzalezb YS, Pangerlb A, Cornberg M. Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets. The International Liver Congress; 10\u201314 April, 2019; Vienna, Austria.","DOI":"10.1016\/S0618-8278(19)31493-8"},{"key":"pone.0235445.ref011","unstructured":"Pedrana A, Howell J, Schr\u00f6der S, et al. Eliminating Viral Hepatitis: The Investment Case. Doha, Qatar: World Innovation Summit for Health, 20182018."},{"key":"pone.0235445.ref012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugpo.2017.07.006","article-title":"Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade","volume":"47","author":"N Scott","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"11","key":"pone.0235445.ref013","doi-asserted-by":"crossref","first-page":"e11028","DOI":"10.2196\/11028","article-title":"Monitoring the Control of Sexually Transmissible Infections and Blood-Borne Viruses: Protocol for the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS)","volume":"7","author":"D Callander","year":"2018","journal-title":"JMIR Res Protoc"},{"key":"pone.0235445.ref014","article-title":"Middleware Supporting Next Generation Data Analytics in Australia","author":"DIR Boyle","year":"2016","journal-title":"Stud Health Technol Inform"},{"issue":"4","key":"pone.0235445.ref015","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1017\/S0950268816002892","article-title":"The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs","volume":"145","author":"CK Aitken","year":"2017","journal-title":"Epidemiol Infect"},{"key":"pone.0235445.ref016","article-title":"The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination","author":"K Safreed-Harmon","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pone.0235445.ref017","unstructured":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement (September 2018). Gastroenterological Society of Australia; 2018."},{"key":"pone.0235445.ref018","unstructured":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement (August 2017). Gastroenterological Society of Australia; 2017."},{"issue":"20","key":"pone.0235445.ref019","doi-asserted-by":"crossref","first-page":"e15626","DOI":"10.1097\/MD.0000000000015626","article-title":"Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis","volume":"98","author":"A Luo","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"pone.0235445.ref020","article-title":"Australia will need to increase testing to achieve hepatitis C elimination","author":"N Scott","year":"2020","journal-title":"Medical Journal of Australia"},{"key":"pone.0235445.ref021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugpo.2017.05.022","article-title":"Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia","volume":"47","author":"J Iversen","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"2","key":"pone.0235445.ref022","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.idh.2018.10.006","article-title":"\"I'm obviously not dying so it's not something I need to sort out today\": Considering hepatitis C treatment in the era of direct acting antivirals","volume":"24","author":"C Wright","year":"2019","journal-title":"Infect Dis Health"},{"issue":"2","key":"pone.0235445.ref023","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S2055-6640(20)30253-3","article-title":"Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access","volume":"4","author":"N Scott","year":"2018","journal-title":"Journal of virus eradication"},{"key":"pone.0235445.ref024","article-title":"The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals","author":"SR Bartlett","year":"2019","journal-title":"Liver Int"},{"issue":"6","key":"pone.0235445.ref025","doi-asserted-by":"crossref","first-page":"e0199174","DOI":"10.1371\/journal.pone.0199174","article-title":"Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era","volume":"13","author":"A Zuckerman","year":"2018","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0235445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T10:02:21Z","timestamp":1667210541000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0235445"}},"subtitle":[],"editor":[{"given":"Yury E","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0235445","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]}}}